Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer
Author Information
Author(s): SH Goey, JW Gratama, JN Primrose, U Ward, RH Mertelsmann, B Osterwalder, J Verweij, G Stoter
Primary Institution: Rotterdam Cancer Institute (Daniel den Hoed Kliniek)
Hypothesis
The combination of IL-2, IFNa-2a, and 5-FU will improve anti-tumour activity in patients with advanced colorectal cancer.
Conclusion
The combination of IL-2 and IFNa-2a with 5-FU has only modest anti-tumour activity in advanced colorectal cancer.
Supporting Evidence
- Six patients achieved a partial response, resulting in a 14% response rate.
- Twenty-four patients had stable disease, and thirteen showed progressive disease.
- The median overall survival was 47 weeks for all patients and 60 weeks for responders.
Takeaway
Doctors tested a new treatment for advanced colorectal cancer, but it didn't work much better than the usual medicine.
Methodology
This phase II study involved treating 44 patients with a combination of IL-2, IFNa-2a, and 5-FU, assessing their responses and side effects.
Potential Biases
Potential bias due to the study design and the small number of patients evaluated for response.
Limitations
The study had a small sample size and a low response rate, which may limit the generalizability of the findings.
Participant Demographics
Patients were predominantly adults under 75 years with histologically confirmed metastatic colorectal cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 5-28%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website